IPP Bureau
Merck to acquire Cidara Therapeutics for $9.2 billion
By IPP Bureau - November 15, 2025
Diversifying its portfolio to include late-phase antiviral agent
Zydus receives final approval from USFDA for Leuprolide Acetate injection
By IPP Bureau - November 15, 2025
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities
By IPP Bureau - November 15, 2025
The observations are procedural in nature and will be responded to within the stipulated time
Caplin Point Laboratories’ subsidiary acquires land in Mexico
By IPP Bureau - November 15, 2025
The investment in land is Rs. 19.85 crore
Pfizer completes up to $10 billion acquisition of Metsera
By IPP Bureau - November 14, 2025
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg
By IPP Bureau - November 14, 2025
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Lupin achieves S&P Global ESG score of 91
By IPP Bureau - November 14, 2025
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
By IPP Bureau - November 14, 2025
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty
By IPP Bureau - November 14, 2025
Terumo BCT and Santersus partner to advance blood purification therapy for sepsis
By IPP Bureau - November 14, 2025
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Hormone therapy for menopause gets green light from FDA
By IPP Bureau - November 14, 2025
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
By IPP Bureau - November 14, 2025
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis opens radioligand therapy facility in Carlsbad, US
By IPP Bureau - November 14, 2025
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
UK MHRA finds gut microbiome research unreliable across labs
By IPP Bureau - November 14, 2025
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Kaiser Permanente’s study highlights power of genetics in preventing heart disease
By IPP Bureau - November 14, 2025
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
